Bruker Settles Patent Disputes with 10x Genomics, Enhancing Collaboration in Spatial Biology

Bruker and 10x Genomics Settle Patent Disputes, Paving the Way for Collaboration in Spatial Biology

In a significant development within the realm of single-cell and spatial biology, Bruker Corporation has reached a settlement agreement with 10x Genomics, Inc. This settlement, announced on May 14, 2025, effectively resolves all patent litigation between the two companies on a global scale. As part of the agreement, Bruker will pay 10x Genomics $68 million, distributed in quarterly installments from the third quarter of 2025 through the second quarter of 2026. Furthermore, Bruker will provide ongoing royalties from its spatial biology product sales for the duration of the licensed patents. This outcome not only alleviates ongoing legal tensions but also opens avenues for enhanced collaboration in the rapidly advancing field of spatial biology.

The settlement underscores the critical importance of intellectual property in the scientific community, particularly for companies engaged in high-stakes innovations like those in spatial biology. 10x Genomics’ CEO, Serge Saxonov, emphasizes the necessity of protecting original scientific contributions to foster innovation and advancement. The agreement is seen as a validation of 10x Genomics’ intellectual property strategy and its ongoing commitment to pushing the boundaries of scientific research. With the settlement, both companies can focus on their core missions without the encumbrance of legal disputes, potentially accelerating discoveries that can lead to breakthroughs in areas such as oncology, immunology, and neuroscience.

In addition to the financial aspects of the settlement, the agreement includes global patent cross-licenses and the complete withdrawal of all ongoing legal proceedings in the U.S., Germany, and at the European Unified Patent Court. This comprehensive resolution not only secures 10x Genomics’ extensive intellectual property portfolio but also enhances its standing in the competitive landscape of spatial biology. As both companies move forward, their commitment to advancing human health through innovative solutions—including instruments, consumables, and software for single-cell and spatial biology—will likely bear fruit, benefiting academic and biopharmaceutical researchers alike.

This resolution comes at a crucial time for both Bruker and 10x Genomics as they navigate the evolving demands of the scientific community. The collaboration stemming from this settlement may lead to new technologies and methodologies that enhance the understanding of complex biological systems, further driving innovation in the life sciences sector. As the companies align their resources and expertise, the potential for collaborative initiatives that bridge gaps in research and development becomes more pronounced, benefiting not only their respective organizations but also the broader scientific landscape.